- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05829512
Translation, Reliability, and Validity of Turkish Version of the Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea (WaLIDD) Score
April 25, 2023 updated by: Halime Arikan, Tokat Gaziosmanpasa University
Currently, there is no agreement in the use of standard questionnaires with adequate validation and structuring measures to classify the severity of dysmenorrhea.
This may explain the variability in prevalence, conditions associated with absenteeism (work, school, etc.), or errors in the diagnostic approach to patients with pelvic pain.
The aim of this study is to conduct a cross-cultural adaptation study of the Turkish version of the working ability, location, intensity, days of pain, dysmenorrhea (WaLIDD) score, a tool designed to allow the identification of women with dysmenorrhea and those at high risk of obtaining medical clearance for the general population.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Dysmenorrhea is the most common gynecological condition worldwide, affecting 90% of women of reproductive age.
It is usually characterized by various symptoms such as pain, nausea, fatigue, depression, diarrhea, headache, insomnia, anxiety, weakness.
According to the pathophysiology of dysmenorrhea, it can be classified as primary dysmenorrhea in which there is no organic disease or secondary dysmenorrhea due to an underlying pelvic abnormality.
Primary dysmenorrhea presents with spasmodic, crampy menstrual pain and discomfort in the absence of pelvic pathology, while secondary dysmenorrhea is associated with a specific pelvic pathology such as endometriosis, adenomyosis, or uterine fibroids.
Working ability, location, intensity, days of pain, dysmenorrhea (WaLIDD) score is an outcome scale designed as a scale type questionnaire (ability to work, location, intensity, days of pain, dysmenorrhea) integrating the features of score dysmenorrhea.
This study will prove whether the Turkish version of the WaLIDD score is valid and reliable in evaluating women with dysmenorrhea.
Statistical Package for Social Sciences (SPSS), version 22.0 computer package program for Windows will be used for statistical analysis.
Statistical data will be expressed as mean±standard deviation (X±SD), median or percent (%).
One-Sample Kolmogorov Smirnov test will be used to show the parametric or nonparametric distribution of the data.
To determine the reliability of the WaLIDD score, test-retest and internal consistency analyzes will be performed at 7-day intervals.
The test-retest value will be evaluated with the Intraclass Correlation Coefficient (ICC) and the internal consistency analysis will be evaluated with the Cronbach α value.
The convergent validity of the WaLIDD score will be made using Pearson correlation analysis after calculating the total scores obtained from the Premenstrual Syndrome Impact Questionnaire, Pain Disability Index, and Big Five Inventory-10 questionnaires.
Statistical significance value will be accepted as p<0.05.
Study Type
Observational
Enrollment (Anticipated)
99
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Halime ARIKAN, PhD
- Phone Number: +90 546 576 51 32
- Email: halimearikan92@gmail.com
Study Locations
-
-
Tokat
-
Merkez, Tokat, Turkey, 60250
- Recruiting
- Tokat Gaziosmanpasa University
-
Contact:
- Halime ARIKAN, PhD
- Phone Number: +90 546 576 51 32
- Email: halimearikan92@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Individuals with dysmenorrhea between the ages of 18-45
Description
Inclusion Criteria:
- Menstrual pain that begins within a few months or within 2 years of menarche
- Pain that starts just before or at the beginning of menstruation,
- Pain in the lower abdomen and back, which may radiate to the inner thighs or both
- Pain, episodic and cramping pain, rarely lasting more than 72 hours,
- Pain similar to one menstrual cycle and additional symptoms such as nausea and vomiting, fatigue, headache, dizziness and sleep disturbances,
- Do not have any diagnosed chronic disease or a past or present psychological disorder,
- Able to speak, read and write Turkish.
Exclusion Criteria:
- Those with psychiatric and cognitive effects such as psychosis, bipolar disorder, eating disorder, moderate or severe depression or somatic symptom disorder,
- Those who participate in psychotherapy because of dysmenorrhea symptoms (currently or in the past), women in pregnancy and lactation,
- Having acute suicidal tendencies, gynecological diseases (hysterectomy, oophorectomy, gynecological cancer, polycystic ovary syndrome, endometriosis, infertility),
- Those who have used antidepressants, benzodiazepines/antipsychotics, oral contraceptives or hormones (e.g. thyroid hormones) in the last 3 months or have had a change in their use,
- With any neurological disorder,
- Can't speak, read or write Turkish.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients group
Individuals with dysmenorrhea
|
Face-to-face questionnaire study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Working ability, location, intensity, days of pain, dysmenorrhea (WaLIDD) score
Time Frame: at first assessment
|
Working ability, location, intensity, days of pain, dysmenorrhea (WaLIDD) score consists of 4 items.
It was designed as a scale-type questionnaire integrating features of dysmenorrhea: 1) Number of anatomical pain locations (no part of the body, lower abdomen, lumbar region, lower extremities, inguinal region), 2) Wong-Baker pain rating (does not hurt, hurts a little, hurts a little more, hurts even more, hurts a lot, hurts a lot more), 3) Number of painful days in the menstrual period (0, 1-2, 3-4, ≥5), and 4) Frequency of pain that prevents performing activities (never, almost never, almost always, always).
Each item has a score between 0 and 3.
The total score ranges from 0 to 12 points.
An increased score indicates a greater degree of dysmenorrhea.
|
at first assessment
|
Premenstrual Syndrome Impact Questionnaire
Time Frame: at first assessment
|
The Premenstrual Coping Measure was developed to assess the ability of Australian women aged 18-49 to cope with premenstrual symptoms.
Each item of the five-point Likert-type scale, which consists of 5 sub-dimensions, is scored between 1 and 5.
No evaluation is made on the Premenstrual Coping Measure total score.
As the score obtained from the sub-dimensions of the scale increases, the ability to cope with premenstrual symptoms also increases.
The lowest score is 27, the highest score is 135.
Increasing score indicates better coping ability.
Turkish version, validity and reliability study of Premenstrual Coping Measure was conducted.
|
at first assessment
|
Pain Disability Index
Time Frame: at first assessment
|
The Pain Disability Index is a self-administered, short and easy scale that measures the extent to which the pain secondary to ongoing discomfort affects the daily life of the individual and the level of disability developed due to this reason.
The scale consists of seven questions.
The individual is asked to rate the effects of pain on seven functional activities of daily living, consisting of family-home responsibilities, leisure time, occupation, social activity, sexual life, and self-care, by giving a score of 0 to 10 for all questions (0= not prevent, 5=moderate prevents, 10= I'am completely inadequate).
The total score ranges from 0 to 70. 40 and above means a high level of disability.
High scores indicate that the disability is severe.
Turkish version, validity and reliability study is available.
|
at first assessment
|
Big Five Inventory-10
Time Frame: at first assessment
|
Big Five Inventory-10 has been brought to the literature as an alternative and short version of Big Five Inventory-44.
The scale consists of 10 items and 5 sub-dimensions.
The scale was evaluated with a 5- point Likert-type rating, as "Strongly Disagree", "Slightly Disagree", "Neither Agree nor Disagree", "Agree Slightly" and "Strongly Agree".
The statements numbered 1-3-4-5-7 in the scale were reversed.
The lowest score is 10, the highest score is 50.
Increasing score and decreasing score according to sub-scales express better and worse personality traits.
Turkish version, validity and reliability study of Big Five Inventory-10 was conducted.
|
at first assessment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2023
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
November 1, 2023
Study Registration Dates
First Submitted
March 31, 2023
First Submitted That Met QC Criteria
April 13, 2023
First Posted (Actual)
April 25, 2023
Study Record Updates
Last Update Posted (Actual)
April 26, 2023
Last Update Submitted That Met QC Criteria
April 25, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 83116987-215
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysmenorrhea
-
Cynthia del Rocío Márquez BeltránUniversity of HuelvaActive, not recruitingPrimary Dysmenorrhea | Menstrual Pain | Menstrual Distress \(Dysmenorrhea\)Spain
-
Cairo UniversityNot yet recruitingPrimary Dysmenorrhea
-
Hacettepe UniversityRecruitingPrimary DysmenorrheaTurkey
-
Cairo UniversityNot yet recruitingPrimary Dysmenorrhea
-
Ankara Yildirim Beyazıt UniversityNot yet recruitingPrimary Dysmenorrhea
-
Ankara Yildirim Beyazıt UniversityNot yet recruiting
-
Cairo UniversityCompleted
-
University of ValenciaCompleted
-
University of SalamancaCompletedDysmenorrhea PrimarySpain
-
Riphah International UniversityCompleted
Clinical Trials on Validity and reliability study
-
Tokat Gaziosmanpasa UniversityRecruiting
-
Gazi UniversityCompleted
-
Gazi UniversityCompleted
-
Atatürk UniversityRecruitingStroke | CognitionTurkey
-
Afyonkarahisar Health Sciences UniversityNot yet recruitingHealthy Volunteers
-
Hacettepe UniversityCompleted
-
Uşak UniversityIstanbul University; Ankara UniversityRecruitingStroke | Quality of Life | Disability PhysicalTurkey
-
Pamukkale UniversityCompleted
-
Akdeniz UniversityRecruiting
-
Kutahya Health Sciences UniversityCompleted